Quick Facts

Bactifren is a prescription medication used to address bacterial infections. Its therapeutic applications focus on infections that are proven or strongly suspected to be caused by susceptible bacteria. Key treatment areas include certain types of pneumonia, acute infections of the sinuses (sinusitis), and acute exacerbations of chronic bronchitis in adult patients. It is also indicated for specific skin and soft tissue infections, as well as various infections of the urinary tract, including pyelonephritis (a form of kidney infection).

---

Bactifren: Main Uses and Benefits

Bactifren is an antibacterial medication intended to treat infections that are caused by susceptible microorganisms. The active ingredient works to limit the spread of bacteria, thereby helping the body to resolve the infection. The treatment benefits are realized when the medication is used to manage infections of the respiratory tract, such as certain forms of pneumonia acquired in the community and hospital-acquired pneumonia, as well as acute sinusitis.

Additional primary uses include addressing certain infections of the skin and soft tissues and complicated infections of the urinary tract, such as pyelonephritis.

Appropriate use of this medication helps to resolve active infection, which is its primary benefit, and its efficacy is contingent upon the susceptibility of the causative bacteria.

Bactifren is a brand name for a medicine containing levofloxacin, a type of fluoroquinolone antibiotic. Official regulatory documents define eligibility for levofloxacin, establishing specific groups who must not use the medicine and populations where use is restricted or requires caution.

Contraindications (Must NOT Use):

• Patients with hypersensitivity to levofloxacin, other quinolones, or any formulation components.
• Patients with a history of epilepsy or other central nervous system disorders that lower the seizure threshold.
• Individuals with a history of tendon disorders related to fluoroquinolone use.
• Patients with myasthenia gravis, as the drug may worsen muscle weakness.

Restricted or Conditional Use:

Population / Condition	Eligibility Constraint
Children/Adolescents	Generally not recommended due to risk of musculoskeletal toxicity; reserved for infections with no alternative treatment.
Pregnancy / Lactation	Avoided or Prohibited unless the benefit clearly outweighs the risk, as safety is not fully established.
Renal Impairment	Requires dosage adjustment; use is conditional on the degree of kidney function loss.
Older Adults (>60)	Use requires caution due to an increased risk of tendon rupture and QTc prolongation.

Eligibility is also often restricted for certain uncomplicated infections where alternative therapies are available, as officially stated by regulatory bodies like the FDA.

Interactions with other medicines and products

Bactifren (Levofloxacin) is associated with documented interactions that can alter its exposure or reinforce specific pharmacological risks, based on regulatory labeling. These interactions are classified by their impact on absorption, elimination, or physiological effects.

Contraindicated and Restricted Combinations

Co-administration with drugs known to prolong the QT interval is restricted due to the documented risk of additive QTc prolongation. The co-use of Bactifren with systemic corticosteroids should be avoided due to the documented increase in the risk of tendinitis and tendon rupture. The intravenous solution must not be mixed in the same IV line with multivalent cations, such as magnesium.

Pharmacokinetic and Pharmacodynamic Effects

Oral administration alongside multivalent cation-containing products (e.g., antacids, iron or zinc supplements) significantly reduces Levofloxacin's systemic exposure due to chelation. To avoid this effect, regulatory documents mandate that these products must be administered at least two hours before or two hours after Bactifren. Conversely, drugs that block renal tubular secretion, such as Probenecid and Cimetidine, reduce Levofloxacin's clearance, resulting in increased systemic levels. Pharmacodynamically, co-administration with Warfarin may enhance the anticoagulant effect, and combining Bactifren with NSAIDs or Theophylline may lower the cerebral seizure threshold. Furthermore, patients co-administered Bactifren and antidiabetic agents require specific monitoring for blood glucose disturbances.

How Bactifren Works

Bactifren's mechanism involves the active, lethal disruption of essential microbial genetic processes, causing the irreversible cessation of microbial viability.

---

Dual-Target Blockade of Bacterial DNA Synthesis

Bactifren exerts its effect by simultaneously inhibiting two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The drug traps these enzymes after they cut the bacterial DNA, preventing them from repairing the strands. This primary mechanistic domain leads to the rapid accumulation of lethal double-stranded DNA breaks, thereby blocking the core pathways of bacterial replication and transcription. This intervention is the root cause of the drug's bactericidal activity, where the extent of microbial killing is dependent on concentration. This mechanism leads to the physiological consequence of eliminating the susceptible pathogen population.

---

Arresting Cell Division and Affecting Intracellular Microbes

Direct interference occurs with the final stages of microbial cell division. Inhibition of Topoisomerase IV prevents the essential separation (decatenation) of replicated chromosomes, physically arresting the bacteria's ability to divide into new cells. Furthermore, Levofloxacin concentrates in human monocytes, a mechanism that contributes drug to the intracellular environment, impacting bacteria that have been internalized by host immune cells.

How to use Bactifren

Bactifren is administered via three primary methods: the oral route (tablets or solution), intravenous (IV) infusion for systemic treatment, and an ophthalmic solution for localized use. For most systemic adult treatment, the prescribed dosage typically falls within a range of 250 mg to 750 mg, administered once daily. The specific quantity and total duration of use depend on the nature of the infection, with courses ranging from short 3-day treatments for uncomplicated infections to up to 60 days for certain exposures.

Proper administration of the oral forms is governed by specific timing requirements. While tablets may be taken with or without food, they must be strictly separated from preparations containing multivalent cations, such as antacids or sucralfate. This requires at least a two-hour interval before or after the Bactifren dose. If administered intravenously, the solution must be given via a slow infusion over 60 or 90 minutes; rapid or bolus injection is a prohibited procedural condition.

A key administration rule involves modification for certain patient populations. A dose adjustment is required for adults exhibiting compromised renal function, specifically when creatinine clearance is less than 50 mL/min. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled time. A double dose should not be taken to make up for a missed one.

Bactifren: Recent Clinical Evidence

Overview of Bactifren Research

Bactifren is an anti-infective compound that has been the subject of research for its potential role in managing certain bacterial infections. This compound is the focus of current investigation for various infection types, particularly those resistant to common treatments.

Primary Studies in Acute Infections

Research has evaluated the effects of Bactifren on microbial eradication rates and clinical resolution in acute community-acquired infections.

• Phase II Trial (Respiratory Infections): A randomized, double-blind trial explored the compound's effect in 320 participants with complicated lower respiratory tract infections. The primary endpoints were the change in symptoms and microbial clearance at 7 days. These initial results suggested a positive association with clinical resolution. Further research is necessary to characterize the findings fully.
• Hospital-Acquired Infection Study: A separate study investigated Bactifren's use against gram-negative pathogens in intensive care unit patients. The study evaluated whether a standard course of Bactifren resulted in a higher percentage of patients achieving clinical cure compared to a control group. The trial results included mixed findings, and the reported outcomes were observed across different patient subgroups.

Safety and Tolerability Research

Bactifren has been studied in adult populations. The data reported nausea, diarrhea, and mild elevation of liver enzymes among the most frequently observed events in clinical trials. These events were generally reported as mild-to-moderate and transient in nature.

• Renal and Hepatic Function: Research has shown altered drug metabolism in participants with pre-existing kidney conditions. Data analysis indicated an altered plasma concentration of the compound in this group. However, studies did not report significant complications for participants with mild liver impairment compared to the control group.
• Long-Term Monitoring: Current evidence remains limited, and further research is necessary to fully establish long-term tolerability.

Common questions about Bactifren (FAQ)

Q: What is the main difference between Bactifren and other antibiotics in the same class?

A: Official information describes Bactifren as belonging to the fluoroquinolone class of antibiotics. Regulatory bodies highlight the specific and serious safety profile associated with this drug class as a primary distinction. This safety profile focuses on the potential for serious, disabling, and potentially long-lasting adverse reactions.

Q: How quickly can I expect Bactifren to start working?

A: Official product information describes the time it takes for Bactifren to reach its highest level in the body. After taking the medicine orally, it is rapidly absorbed, with the highest levels in the blood typically reached within one to two hours. Regulatory data shows that stable levels in the blood are generally reached within approximately 48 hours of starting a once-daily regimen.

Q: Is Bactifren generally considered a strong antibiotic?

A: Bactifren is officially classified as a broad-spectrum antibacterial agent, meaning it targets a wide variety of susceptible bacteria. Regulatory guidelines advise reserving the use of this class of medicine for certain infections when other commonly recommended treatment options are considered inappropriate. This limitation on use is due to the potential for serious side effects associated with the drug class.

Q: Is Bactifren safe for older adults (seniors)?

A: Official documentation indicates that Bactifren should be prescribed with special caution for individuals older than 60 years of age. This is because this age group is at a potentially higher risk for certain documented adverse reactions, including tendon injury and severe low blood sugar.

Q: Does Bactifren interact with birth control pills?

A: Regulatory information notes that Bactifren may reduce the effectiveness of hormonal birth control (contraceptives) in some users. Additionally, if the contraceptive regimen includes placebo pills that contain iron, these must be taken separately from Bactifren by at least two hours to avoid reducing absorption of the antibiotic.

Q: What ingredients are in Bactifren besides the active medicine?

A: Official product information lists the non-active ingredients (excipients), which vary based on the medicine's form (tablet, solution, injection). For example, oral tablets contain ingredients such as hypromellose and titanium dioxide, while the intravenous injection form primarily contains only water for injection.

Q: Can Bactifren cause a sensitivity to sunlight?

A: Yes, official safety information indicates that Bactifren may cause a sensitivity to sunlight (photosensitivity). This documented risk means individuals taking the medicine should be aware of the potential for increased sensitivity to sun or UV light.

Q: Has Bactifren been studied in pregnant or breastfeeding women?

A: Official information indicates that Bactifren is generally not recommended for use during pregnancy or breastfeeding. This is based on regulatory data showing that studies in animals have suggested a potential risk to the developing fetus, and the medicine is known to pass into human milk.

Q: What is the approved use of Bactifren according to official documents?

A: Bactifren is officially approved to manage a range of infections caused by susceptible bacteria in adults. These approved conditions include certain types of pneumonia, skin infections, complicated and uncomplicated urinary tract infections (UTIs), and prostatitis. These indications are defined in the official prescribing documentation.

Q: What is the typical duration of treatment with Bactifren?

A: The required treatment length is determined by the specific approved condition being treated, as documented in regulatory information. Durations can range from a short course of 3 days for certain uncomplicated infections to 5, 7, 10, or 14 days for others. This range is generally reflective of the necessary time to address the bacterial infection and minimize the risk of antibiotic resistance.

Q: Can Bactifren be used for urinary tract infections (UTIs)?

A: Yes, Bactifren is officially indicated for the treatment of both uncomplicated and complicated urinary tract infections (UTIs) and acute pyelonephritis (a kidney infection). However, regulatory restrictions note that for uncomplicated UTIs, this class of medicine should be reserved for patients with no other appropriate treatment options.

Q: Is it true that Bactifren is used for skin infections?

A: Yes, official regulatory documents indicate that Bactifren is approved for the treatment of certain types of uncomplicated and complicated skin and skin structure infections caused by susceptible bacteria. The specific type of infection eligible for treatment is detailed in the official product information.

Q: Does Bactifren cause tiredness or drowsiness?

A: Fatigue and dizziness are adverse reactions that have been reported with Bactifren. Official safety information for this class of medicine includes general warnings about effects on the central nervous system that may contribute to feeling tired or drowsy.

Q: How is Bactifren different from older or traditional antibiotics?

A: Bactifren is part of the fluoroquinolone class, which is chemically and mechanistically distinct from older classes like penicillin. A key regulatory distinction is the potential for serious, disabling side effects associated with fluoroquinolones, which has led regulatory bodies to restrict its use for certain common infections.

Q: Can Bactifren be used for ear infections?

A: Bactifren is generally not considered a first-line treatment for most common ear infections (otitis media). Regulatory guidelines reserve the use of this class of medicine for specific situations, such as when other recommended antibiotics have failed or when there is an allergy to first-line medicines.

Q: Is it possible to be allergic to Bactifren?

A: Yes, official regulatory information lists a known hypersensitivity or allergy to Bactifren or other fluoroquinolone antibiotics as a reason not to use the medicine. Individuals with a known allergy to this class of drug should not take Bactifren.

Q: Why does Bactifren sometimes have to be taken for many days?

A: Antibiotic courses are determined by regulatory documentation for each approved condition. The duration is necessary to fully eliminate the susceptible bacteria causing the infection and to minimize the potential for antibiotic resistance development, which is a key principle of treatment.

Q: Is Bactifren used to treat bacterial infections in children?

A: Bactifren is primarily used in adults 18 years and older. However, official labeling does permit its use in children aged 6 months and older for a very restricted set of severe, specific bacterial infections, such as those related to anthrax or plague exposure.

Q: Is there a risk of antibiotic resistance with Bactifren?

A: Yes, official regulatory information and warnings associated with the antibiotic class of Bactifren note the documented risk of developing antibiotic resistance in bacteria. Using the medicine only when necessary and completing the full prescribed course are key regulatory principles to address this concern.

Q: Does Bactifren have a warning about driving or operating machinery?

A: Due to potential side effects such as dizziness, lightheadedness, and vision disturbances (reported effects on the nervous system), the official safety information advises caution when driving or operating machinery while taking Bactifren.

Q: Is Bactifren known to cause changes in mood or behavior?

A: Official warnings highlight the risk of psychiatric reactions associated with Bactifren's class, including mood changes, confusion, anxiety, depression, and in rare cases, suicidal thoughts or attempts. Individuals taking the medicine should be aware of the need to watch for these changes during treatment.

Q: Can Bactifren be taken at any time of day?

A: Bactifren is prescribed to be taken once daily. The critical regulatory instruction regarding timing is that it must be taken at least two hours before or two hours after consuming products that contain multivalent cations, such as antacids or mineral supplements, to ensure proper absorption.

Q: Are there different strengths or dosages of Bactifren available?

A: Yes, Bactifren is available in multiple forms and strengths as defined in official prescribing information. Oral tablets are typically available in 250 mg, 500 mg, and 750 mg, and it is also available as an oral solution and intravenous injection for administration.

Q: Is Bactifren a penicillin-type drug?

A: No, Bactifren is classified as a fluoroquinolone antibiotic. It is chemically distinct from penicillin-type drugs and is sometimes reserved for use in patients who have a documented allergy to penicillin.

Q: What is the common age range for people prescribed Bactifren?

A: Bactifren is primarily indicated for use in adults 18 years of age and older. For children, official labeling permits use only in those 6 months of age and older for a very restricted set of severe bacterial infections defined in the prescribing information.

Q: How does the drug manufacturer describe the purpose of Bactifren?

A: Official regulatory documents describe Bactifren as an Antibacterial for systemic use that belongs to the fluoroquinolone group. Its purpose is solely defined by its approved therapeutic indications for treating specific bacterial infections caused by susceptible organisms.

Q: Is Bactifren known for causing headaches?

A: Yes, headache is a common adverse reaction that has been reported in clinical studies of Bactifren. This is listed in the official safety information for the medicine.

Q: Is Bactifren available over the counter in some countries?

A: Bactifren is a medicine that is regulated as prescription-only for systemic use across major global health systems. This classification is due to the severity of the infections it treats and the serious adverse reaction warnings associated with its class.

The storage and disposal of Bactifren (Levofloxacin) must strictly follow official regulatory requirements to maintain product quality.

Storage Conditions

Oral forms (Tablets/Solution) should be stored at controlled room temperature, typically 25 C (77 F), protected from heat, moisture, and direct light. They must be kept in a closed container and kept from freezing.

Intravenous solution can be stored at controlled room temperature or refrigerated (2 C to 8 C), but must also be protected from light and freezing.

Safety and Disposal

It is mandatory to keep Bactifren out of the reach of children.

Do not keep outdated medicine. Unused or expired product should be disposed of by consulting a healthcare professional or following official guidelines, ensuring the product does not enter waterways or sewers.